Hospital management of hyperglycemia in the context of COVID-19: evidence-based clinical considerations

Página do item simplificado
dc.contributor.authorMendes, Thiago Bosco [UNESP]
dc.contributor.authorCâmara-de-Souza, Alexandre Barbosa
dc.contributor.authorHalpern, Bruno
dc.contributor.institutionUniversidade Estadual Paulista (UNESP)
dc.contributor.institutionUniversidade de São Paulo (USP)
dc.contributor.institutionHospital 9 de Julho
dc.date.accessioned2022-04-29T08:40:45Z
dc.date.available2022-04-29T08:40:45Z
dc.date.issued2022-12-01
dc.description.abstractThe COVID-19 pandemic led to an unprecedented crisis, and early on, it has been shown that diabetes is an important risk factor for complications and mortality in infected patients, as demonstrated by several studies. Moreover, hyperglycemia, regardless of whether patients have diabetes, is associated with poorer outcomes, which suggests that adequate monitoring and treatment of elevated glycemia in the hospital setting can improve patient outcomes. In patients with COVID-19, glycemic control may be impaired as a consequence of the infection itself (aggravating pre-existing diabetes and potentially precipitating new-onset diabetes), inflammation, or corticosteroid use—a well-established therapy to reduce COVID-19 complications, especially in the intensive care unit. This article reviews the link between diabetes and hyperglycemia, and COVID-19, with a brief review of potential mechanisms, along with emerging evidence on the effect of glycemic control on COVID-19 outcomes, especially in hospital settings.en
dc.description.affiliationDepartment of Internal Medicine Hospital das Clínicas São Paulo State University (UNESP)
dc.description.affiliationDepartment of Endocrinology Hospital das Clínicas University of São Paulo (USP)
dc.description.affiliationDepartment of Endocrinology Hospital 9 de Julho, Rua Alves Guimarães, 462, cj. 72, Pinheiros, SP
dc.description.affiliationUnespDepartment of Internal Medicine Hospital das Clínicas São Paulo State University (UNESP)
dc.identifierhttp://dx.doi.org/10.1186/s13098-022-00808-x
dc.identifier.citationDiabetology and Metabolic Syndrome, v. 14, n. 1, 2022.
dc.identifier.doi10.1186/s13098-022-00808-x
dc.identifier.issn1758-5996
dc.identifier.scopus2-s2.0-85126185907
dc.identifier.urihttp://hdl.handle.net/11449/230558
dc.language.isoeng
dc.relation.ispartofDiabetology and Metabolic Syndrome
dc.sourceScopus
dc.subjectAntihyperglycemic drugs
dc.subjectCorticosteroids
dc.subjectCOVID-19
dc.subjectDiabetes
dc.subjectHyperglycemia
dc.subjectInsulin
dc.titleHospital management of hyperglycemia in the context of COVID-19: evidence-based clinical considerationsen
dc.typeResenha
unesp.author.orcid0000-0001-8349-3303[1]
unesp.author.orcid0000-0002-4029-3667[2]
unesp.author.orcid0000-0003-0973-5065[3]

Arquivos

Coleções

Artigos - Hospital das Clínicas (HC) - Botucatu